14.39

3.15% +0.44

After Hours: 14.4302 0.0402 +0.28%

Range Cancer Therapeutics ETF (CNCR)

Overview News Price History Discussions Forecast Dividend History

Range Cancer Therapeutics ETF stock is currently priced at $14.39, with a 24-hour trading volume of 3,231. It has seen a +3.15% increased in the last 24 hours and a -8.92% declined in the past month. The chart indicates a potential bullish trend, as the stock is above the $13.99 pivot point. If it approaches the $14.48 resistance level, significant changes may occur.

Previous Close:

$13.95

Open:

$13.9658

24h Volume:

3,231

Market Cap:

$N/A

Revenue:

Net Income/Loss:

P/E Ratio:

EPS:

Net Cash Flow:

1W Performance:

+1.98%

1M Performance:

-8.92%

6M Performance:

+52.11%

1Y Performance:

+14.84%

1D Range:

$13.94

$14.43

52W Range:

$9.22

$17.96

Range Cancer Therapeutics ETF Stock (CNCR) Company Profile

Name

Range Cancer Therapeutics ETF

Sector

Financial (4475)

Industry

Exchange Traded Fund (2992)

Phone

800-617-0004

Address

Employee

Twitter

@LoncarFunds

Next Earnings Date

Latest SEC Filings

CNCR's Discussions on Twitter

Range Cancer Therapeutics ETF Stock (CNCR) Latest News

Range Cancer Therapeutics ETF Stock (CNCR) Financials Data

There is no financial data for Range Cancer Therapeutics ETF (CNCR). Check out other stocks for more information.

The investment seeks to track the total return performance, before fees and expenses, of the Loncar Cancer Immunotherapy Index. The index is composed of the common stock of approximately 25 pharmaceutical or biotechnology companies identified by the fund's index provider, as having a high strategic focus on the development of drugs that harness the body's own immune system to fight cancer. The adviser attempts to invest all, or substantially all, of its assets in the component securities and ADRs that make up the index. Normally it will invest at least 80% of its total assets in the component securities of the index. The fund is non-diversified.